【ChiCTR-TRC-14004478】圍手術期輸血指征評分(Peri-Operative Transfusion Trigger Score, POTTS)安全性與有效性的多中心,隨機,對照臨床研究
ChiCTR-TRC-14004478
正在进行
/
/
/
2014-04-10
/
/
Elective surgery with potential massive blood loss requiring blood transfusion
圍手術期輸血指征評分(Peri-Operative Transfusion Trigger Score, POTTS)安全性與有效性的多中心,隨機,對照臨床研究
圍手術期輸血指征評分(Peri-Operative Transfusion Trigger Score, POTTS)安全性與有效性的多中心,隨機,對照臨床研究
圍手術期輸血指征評分(Peri-Operative Transfusion Trigger Score, POTTS)安全性與有效性
随机平行对照
其它
Randomized
pen label
Prince of Wales Hospital, Shatin, Hong Kong
/
20
/
2014-02-20
1990-01-01
/
1. Age older than 14 weeks old; 2. Live in an area of altitude shorter than 2500 m most of the time; 3. Estimated intraoperative blood loss more than 1000ml, or more than 20% of total blood volume.;
请登录查看1. Emergency surgery; 2. Patients with physical status of ASA class V or above; 3. Patients with known severe haematological disorders; 4. Patients with known haemaglobinopathy; 5. Acute hypervolemic haemodilution is planned; 6. Patients with known metastatic cancer or more than one neoplasm concurrently; 7. Other conditions that may preclude the patients from the study, such as language barrier, psychiatric disorders, unable to attend research center for follow up; 8. Patients who enrolled to another research study or are taking experimental medication in last 3 months prior to this study; 9. Not suitable for the study, after assessment by the investigators.;
请登录查看Prince of Wales Hospital, Shatin, Hong Kong
/
Prince of Wales Hospital, Shatin, Hong Kong的其他临床试验
Prince of Wales Hospital, Shatin, Hong Kong的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示:#脐带间充质干细胞(#hUC-MSCs)
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点,索弗度肽(survodutide)成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构:国家卫生健康委办公厅、 2026-11-10
-
颁布机构:国家卫健委(原国家卫计委) 2026-11-10
-
颁布机构:国家药品审评中心(CDE) 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构:国家市场监督管理总局 2026-11-07
-
颁布机构:国家市场监督管理总局 2026-11-07
-
颁布机构:国家市场监督管理总局 2026-11-04

